ALXN1850
Sponsors
Alexion Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc.
Conditions
Hypophosphatasiahypophosphatasia
Phase 1
Phase 3
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
Active, not recruitingNCT06079359
Start: 2024-05-14End: 2028-08-24Updated: 2026-02-18
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
Active, not recruitingNCT06079372
Start: 2024-04-02End: 2028-02-29Updated: 2026-03-12
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
Active, not recruitingNCT06079281
Start: 2024-01-03End: 2028-03-29Updated: 2026-03-12
A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 Versus Placebo Administered Subcutaneously in Pediatric (2 to < 12 years of age) Participants with Hypophosphatasia Who Have Not Received Previous Treatment with Asfotase Alfa
RecruitingCTIS2023-505675-73-00
Start: 2024-04-26Target: 13Updated: 2025-07-09
A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 (Recombinant Alkaline Phosphatase) Administered Subcutaneously in Adolescent (12 to < 18 years of age) and Adult Participants with Hypophosphatasia Who Have Not Previously Been Treated with Asfotase Alfa (Hickory)
RecruitingCTIS2023-505673-32-00
Start: 2024-08-05Target: 34Updated: 2025-07-02
A Phase 3, Randomized, Open-label, Parallel-arm, Active-controlled, Multicenter Study to Evaluate Safety and Efficacy of ALXN1850 Versus Asfotase Alfa Administered Subcutaneously in Pediatric Participants (2 to < 12 years of age) with Hypophosphatasia (HPP) Previously Treated with Asfotase Alfa (Chestnut)
WithdrawnCTIS2023-505674-15-00
Target: 7Updated: 2024-04-17